诺和诺德近期发起多笔战略性收购,加速布局新一代疗法

制药网
Dec 10

为扩充产品管线、对冲 GLP‑1 专利到期风险,诺和诺德在2025年正加速转型与布局未来。据悉,在近期其已发起多笔大额收购,获得了多款高潜力创新药。12月9日,诺和诺德宣布,已成功完成对生物制药公司Akero Therapeutics的收购。此次收购以每股54美元现金(总价值达47亿美元)及一项不可转让的或有价值权(CVR)作为交易对价,全面收购了Akero所有已发行的普通股及等价物。随着交易的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10